|
Synonyms: BYM-338 | BYM338
Compound class:
Antibody
Comment: Bimagrumab is an investigational monoclonal antibody that binds to activin type II A and B receptors to block activin and myostatin signalling in muscles and adipose tissue. It was originally intended to combat age-related muscle loss and other muscle-wasting conditions. Most recently it has been repositioned as a counter measure for the muscle loss in patients using GLP-1 agonist anti-obesity drugs such as semaglutide and tirzepatide.
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
| Bioactivity Comments |
| Bimagrumab inhibits myostatin binding to ACVR2B, thereby blocking myostatin-induced signalling as measured by a Smad dependent reporter gene assay [1]. |
| Selectivity at catalytic receptors | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Key to terms and symbols | Click column headers to sort | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||
